Aurora Therapeutics

Aurora Therapeutics is redefining the development and approval of personalized gene-editing medicines for patients with rare diseases. The company integrates cutting-edge CRISPR engineering, comprehensive regulatory pathways, and a modular CMC framework to advance multiple mutation-specific therapies in parallel. Aurora’s approach addresses the fundamental economic and operational barriers that have historically hindered treatments for rare mutations, enabling CRISPR therapies to reach patient population scale.